Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis

Figure 1 Forest plot of randomized (RCTs) and non-randomized (NRCTs) controlled trials evaluating the effect of post-operative antiviral therapy on hepatocellular carcinoma (HCC) recurrence after curative therapy (RevMan, version 5; The Cochrane Collaboration, Copenhagen, Denmark). A: 1-year recurrence, the Mantel-Haenszel method; B: 2-year recurrence, the Der Simonian and Laird method; C: 3-year recurrence, the Der Simonian and Laird method; D: 5-year recurrence, the Mantel-Haenszel method.

Figure 2 Forest plot of randomized (RCTs) and non-randomized (NRCTs) controlled trials evaluating the effect of post-operative antiviral therapy on HCC mortality after curative therapy (RevMan, version 5; The Cochrane Collaboration, Copenhagen, Denmark). A: 1-year mortality, the Mantel-Haenszel method. B: 2-year mortality, the Mantel-Haenszel method; C: 3-year mortality, the Der Simonian and Laird method; D: 5-year mortality, the Mantel-Haenszel method; E: 7-year mortality, the Mantel-Haenszel method.

Figure 3 Forest plot of randomized (RCTs) and non-randomized (NRCTs) controlled trials evaluating the effect of post-operative antiviral therapy on the 3-year mortality of HCV-related HCC patients after curative therapy (RevMan, version 5; The Cochrane Collaboration, Copenhagen, Denmark). A: Comparison between patients with sustained virologic response (SVR) and those without sustained virologic response (non-SVR), the Mantel-Haenszel method; B: Comparison between non-SVR patients and control subjects, the Mantel-Haenszel method; C: Comparison between SVR patients and non-SVR patients plus control subjects, the Mantel-Haenszel method.